Smith & Nephew PLC
Most Recent
How JNJ Aims to Regain Its Position in the Knee Implant Business
Johnson & Johnson (JNJ) is the third-largest player in the global knee implant market and the second-largest player in markets outside the United States.
Johnson & Johnson’s Acclarent Aera Balloon Dilation System
On February 27, 2018, Johnson & Johnson’s subsidiary Acclarent announced FDA approval for the expanded indication for Acclarent Aera.
How JNJ’s Orthopedic Medical Devices Performed in 4Q17 and 2017
In 4Q17, Johnson & Johnson’s (JNJ) hip medical devices business generated revenue of $364 million.
What Zimmer Biomet’s Progress II Study Success Could Mean
On December 22, 2017, Zimmer Biomet Holdings (ZBH) published the results of its Progress II trial, and the results were positive.
Stryker’s Inorganic Growth Strategy Continues to Boost Growth
Stryker’s acquisition-driven growth strategy Stryker (SYK) has been growing at a fast pace through inorganic growth. It has undertaken a number of strategic acquisitions recently. In 3Q17, acquisitions contributed approximately 0.6% of the company’s YoY (year-over-year) sales growth, and in the first three quarters of 2017, Stryker acquisitions contributed ~3.2% of the company’s sales growth […]
Stryker and Zimmer Biomet Holdings Settled a Trade Secret Case
On November 28, 2017, Howmedica Osteonics, an orthopedics subsidiary of Stryker (SYK) and Zimmer Biomet Holdings (ZBH), settled a trade secret case.
What’s behind Zimmer Biomet’s Recent Stock Downtrend?
Zimmer Biomet Holdings (ZBH) ended trading at $108.70 on November 7, 2017. Currently, ZBH stock’s 50-day moving average stands at $117.60.
Asia-Pacific Still Zimmer Biomet’s Strongest Geography
Zimmer Biomet Holdings witnessed a strong performance in its Asia-Pacific region. It contributed 16% to the company’s total sales.
How Mako Robots Are Driving Stryker’s Sales in 2017
Mako sales in 3Q17 In 3Q17, Stryker sold 33 Mako robots, compared with 30 robots in 3Q16. In 2Q17, Stryker installed 26 Mako robots. Of these 33 robots, 23 were installed in the United States. Around 40% of US sales are expected to be in competitive accounts. Stryker is training surgeons on its total knee application […]
Stryker: Analysts’ Recommendations before Its 3Q17 Earnings
Stryker (SYK), the second-largest orthopedic device developer, is set to announce its 3Q17 earnings results on October 26, 2017.
ZBH’s Persona Partial Knee Launch Expands Knee Implant Portfolio
On September 11, 2017, Zimmer Biomet Holdings (ZBH) announced the launch of its Persona Partial Knee System.
Stryker Won the Patent Case against Zimmer Biomet Holdings
On July 12, 2017, a US district court judge increased the penalties to be paid by Zimmer Biomet Holdings to Stryker related to its patent infringement case.
Recent Product Launches Expand Stryker’s Orthopedics Business
In 1Q17, Stryker (SYK) reported YoY growth of ~18.5%. One of the contributing factors its growth is the company’s innovative product portfolio.
Stryker’s MAKO Total Knee Implant: Robotics in Orthopedics
In March 2017, Stryker (SYK) announced the commercial launch of its robotic-arm assisted total knee application to be used with its MAKO system.
What Drove Medtronic’s MITG Segment Growth?
Medtronic (MDT) reported ~$7.9 billion in worldwide revenues in fiscal 4Q17.
Inside the Latest Capability Advancement in Johnson & Johnson’s Orthopedics
On January 9, JNJ’s Medical Device division announced its Orthopedic Episode of Care Approach, a data-driven program that will accelerate value-based care.
What Impacted Zimmer Biomet’s Reconstructive Segment?
In 3Q16, Zimmer Biomet Holdings (ZBH) reported total sales of $1.83 billion. It represented YoY (year-over-year) constant currency growth of 3.5%.
Here’s What’s Driving Medtronic’s MITG Segment
Of Medtronic’s ~$7.3 billion in worldwide revenues in fiscal 2Q17, ~$2.5 billion came from Medtronic’s MITG segment, representing ~34% of the company’s total revenues.
Must-Know Details of Zimmer Biomet’s Clinical Graphics Acquisition
On September 15, 2016, Zimmer Biomet Holdings (ZBH) announced the strategic acquisition of Clinical Graphics.
A Look at PRITX’s Portfolio Changes So Far in 2016
PRITX aims to invest in established companies that are either headquartered outside of the United States or whose main businesses are carried out outside the United States.
How Stryker Plans to Leverage the Under-Tapped Europe Opportunity
Europe represents a potential growth opportunity for Stryker, as the company currently has a low market share in Europe compared to other developed markets.
Discussing Stryker’s Expansion and Growth in Emerging Markets
Stryker registered ~$2.8 billion in revenue in 2Q16. Around 72% of this was generated by its US business, and the remainder came from international sales.
Zimmer Biomet’s Realized Synergies, Market Position after Integration
Zimmer Holdings acquired Biomet in June 2015 and formed Zimmer Biomet Holdings (ZBH). The acquisition established the combined company as the second-largest player in the orthopedics medical device market segment.
Seeking Returns by Investing Mainly in European Equity Securities
The Brown Advisory WMC Strategic European Equity Fund Investor Shares generally invests at least 80% of its net assets in European companies.
Company & Industry Overviews Industrials and Discretionary Helped AEDAX in 1Q16
AEDAX fell 0.9% in 1Q16. But it still ranked second best among the 12 funds in this review.
Zimmer Biomet Faces Market Share Erosion in the Knee Implant Market
Zimmer Biomet (ZBH) is the leading provider of knee implants in the United States. It has approximately 40% market share, followed by Stryker, Johnson & Johnson, and Smith & Nephew.
Company & Industry Overviews Solid Metrics Make BIAHX Less Volatile Than Peers
From a NAV return standpoint, BIAHX stood third among its peers for the one-year period until March 15, 2016. Since the ECB announcement of stimulus measures, the fund is fifth.
Company & Industry Overviews Does the MFS International Growth Fund Deserve Your Attention?
The MFS International Growth Fund’s standard deviation, or the volatility of returns, in the one-year period until February 29 was 15.3%.
Company & Industry Overviews BIAHX: Could It Be a Candidate for Your Shortlist?
The Brown Advisory – WMC Strategic European Equity Fund (BIAHX) was managing assets worth $1.1 billion as of January 2016.
